Wu, Tong
Fan, Rong
Bai, Jian
Yang, Zhao
Qian, Yun-Song
Du, Lu-Tao
Wang, Chun-Ying
Wang, Ying-Chao
Jiang, Guo-Qing
Zheng, Dan
Fan, Xiao-Tang
Zheng, Bo
Liu, Jing-Feng
Deng, Guo-Hong
Shen, Feng
Hu, He-Ping
Ye, Yi-Nong
Zhang, Qing-Zheng
Zhang, Jing
Gao, Yan-Hang
Xia, Jie
Yan, Hua-Dong
Liang, Min-Feng
Yu, Yan-Long
Sun, Fu-Ming
Gao, Yu-Jing
Sun, Jian
Zhong, Chun-Xiu
Wang, Yin
Wang, Hui
Kong, Fei
Chen, Jin-Ming
Wen, Hao
Wu, Bo-Ming
Wang, Chuan-Xin
Wu, Lin
Hou, Jin-Lin
Liu, Xiao-Long
Wang, Hong-Yang
Chen, Lei
Funding for this research was provided by:
National Natural Science Foundation of China (U21A20376, 81988101, 81790633, and 81830054)
Local Innovative and Research Teams Project of Guangdong Pearl River Talents Program (2017BT01S131)
Sanming Project of Medicine in Shenzhen (SZSM201911001)
National Science Foundation of Shanghai (21XD1404600, 17ZR143800, 21JC1406600, and 22140901000)
Article History
Received: 20 September 2022
Accepted: 20 December 2022
First Online: 5 January 2023
Declarations
:
: This trial was conducted in nine clinical sites across China, and all the participants were enrolled in Prospective suRveillance for very Early hepatoCellular cARcinoma (PreCar) project. It adhered to the Declaration of Helsinki and the Good Clinical Practice guidelines. The protocol was approved by the ethics committee at all participating hospitals. A written informed consent was provided by every participant.
: Not applicable.
: The authors declare no competing interests.